Dr Iakov Vladislavovich Efimenko, MD | |
1475 W 49th Pl, Hialeah, FL 33012-3113 | |
(305) 558-2500 | |
Not Available |
Full Name | Dr Iakov Vladislavovich Efimenko |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 1475 W 49th Pl, Hialeah, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598497299 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | TRN36144 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Iakov Vladislavovich Efimenko, MD 100 Nw 6th St Apt 1702, Miami, FL 33136-4132 Ph: (954) 461-9452 | Dr Iakov Vladislavovich Efimenko, MD 1475 W 49th Pl, Hialeah, FL 33012-3113 Ph: (305) 558-2500 |
News Archive
Mice with a lower calorie intake live longer and are both healthier and leaner. A team of researchers funded by the SNSF may have found the reason for this positive effect: much of it is down to gut microbial communities and how they affect the immune system.
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria decided to cancel Round 11 grant approval during a two-day meeting in Accra, Ghana, that concluded on November 22, according to a Global Fund press release (11/23).
Transformation in U.S. health care delivery systems and associated quality measurements in the wake of reforms implemented by Affordable Care Act might be most impactful within community health centers (CHC).
ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new study results that demonstrate hospitals could realize substantial savings by substituting Flexi-Seal FMS for traditional fecal management methods.
Osiris Therapeutics, Inc., the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency (EMA) has designated Osiris as the Orphan Drug title holder for Prochymal (remestemcel-L).
› Verified 3 days ago